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Introduction
Pharmaceutical care was developed initially in the 
early 1990s,1 and later recognised as a process to 
improve the quality of pharmacotherapy. Within 
this process of implementing and optimizing phar-
macotherapy, a need for identification and correc-
tion of problems was noted in pharmacotherapy of 
patients. This led to the concept of drug-related 
problems (DRPs), defined as problems in the 
pharmacotherapy of the individual patient that 
actually or potentially interfere with desired health 
outcomes. According to Pharmaceutical Care 
Network Europe (PCNE) classification,2 a DRP is 
‘an event or circumstance involving drug therapy 
that actually or potentially interferes with desired 
health outcomes’ and DRPs are classified as dos-
ing problems, adverse drug reactions (ADRs), 
drug–drug interaction, inappropriate prescription 
and patient adherence to the drug. In DRPs, the 
impact of the problem on health outcome of the 
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Background: Drug related problems (DRPs) occur frequently among psychiatric patients due 
to common prescribing errors and complex treatment schedules. Clinical pharmacists (CPs) 
are thought to play an important role in preventing DRPs and, consequently, to increasing 
the quality of inpatient care. There is, however, limited information available on DRPs within 
the psychiatric field in Denmark. The aim of this study was to identify rates and correlates 
of pharmacotherapy-related problems among psychiatric inpatients in a Danish psychiatric 
hospital.
Methods: A retrospective descriptive study was conducted by two CPs and data were obtained 
from the medical records available in two psychiatric wards. Chart-reviews were conducted 
for the period of June 2015 to February 2017. The analyses focussed on the prevalence of 
DRP categories, implementation and acceptance rates, and drugs associated with the DRPs. 
Extracted data were discussed with the wards’ physicians and registered in a DRP-database.
Results: In total, 607 medical records were reviewed and, on average, 2.5 DRPs per 
medication review were found. There was a positive correlation between the number 
prescribed drugs and the average number of DRPs. The most frequent categories of DRPs 
were ‘drug dosage’, ‘inappropriate drug’ and ‘interactions’. The drugs represented most 
frequently in DRPs were olanzapine, quetiapine and pantoprazole. The overall acceptance rate 
was 49% with 33% of those implemented clinically.
Conclusion: DRPs were commonly observed among psychiatric patients, particularly in those 
with multiple prescriptions, in relation to drugs dosage, inappropriate prescriptions and drug 
interactions. Particular attention must be paid to olanzapine, quetiapine and pantoprazole. 
Strategies to minimise DRPs among psychiatric patients are warranted and CPs can play an 
important role.
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pharmacotherapy must be reported. DRPs can 
occur within the entire course of implementing 
pharmacotherapy, including prescribing, dispens-
ing, and drug usage phases.3
Previous studies have indicated that hospitalised 
patients often face DRPs. In Norway,4 2.6 DRPs 
were reported to occur per patient in a medical 
ward. In addition, occurrence of DRPs per patient 
has been found to increase with the number of 
prescribed drugs in a positive and linear fashion.4 
DRPs often cause safety issues for hospitalised 
patients and consequently lead to reduced quality 
of life, increased hospital stay, increased overall 
cost for health care systems and increase risk of 
morbidity and mortality.4–6 Therefore, improving 
drug therapy by preventing DRPs would be ben-
eficial to enhance patients’ quality of life, and to 
reduce treatment-related costs. In addition, insur-
ance issues must be taken into account in coun-
tries where a welfare-based healthcare system 
might not be available. Several tools and strategies 
have been developed to address DRP issues, for 
example, computerised alerts. Several studies 
have also highlighted the potential role of clinical 
pharmacists (CPs). The role of the CP continue to 
increase in diversity, and CPs are recognized as 
part of the multidisciplinary team within health-
care systems. Among their roles, improving medi-
cation management within the hospital setting has 
been noted, including medication review.7,8 CPs 
increase the quality of inpatient care and reduce 
the number of DRPs.9,10 Since DRPs can occur in 
any medication specialty and in any wards in the 
hospital, many hospitals around the globe have 
implemented medication review by CPs. Denmark 
has also implemented the performamce of medi-
cation reviews by CPs; however, little is known 
about DRPs in psychiatric hospitals and role of 
CPs. Harm and early death can be the result of 
prescribing errors in psychiatric patients.11,12 With 
common prescribing errors,11–13 such as incorrect 
or irrational drug choices, failure to apply clinical 
knowledge,14 or complex treatment schedule due 
to psychiatric and somatic comorbidities,13,15 psy-
chiatric patients are at risk of facing DRPs. 
Furthermore, treatment with antipsychotics 
increases the risk of DRPs because of the associa-
tion with interactions and side effects that can be 
potentially fatal.15 Studies have shown that psychi-
atric patients frequently experience DRPs,11,13,15–17 
and it is known that the type of DRP differs mark-
edly among different patient groups.18 Only a few 
studies have looked into the prevalence and type 
of DRPs in the psychiatric setting.15–17,19 Two of 
these studies found ‘drug interaction’ as the larg-
est category of DRPs,15,19 whereas the other stud-
ies found ‘inappropriate drug’ and ‘dosage’, along 
with antipsychotic polypharmacy and the need for 
monitoring.16,17 Therefore, this study aimed at 
identifying the pattern and type of DRPs in a psy-
chiatric hospital in Denmark and the acceptance 
and implementation rate of DRPs, along with 
clarification of which classes and drugs are mainly 
involved in DRPs.
Methods
Design, setting and study population
This study was designed as a retrospective 
descriptive study using data registered in a Danish 
Drug Related Problems Database (DRP-
database).20 Data were anonymised in the DRP 
database. The database is owned by Amgros that 
holds an umbrella approval, which permits users’ 
access without a need for an extra approval. No 
ethical approval was therefore required for this 
study based on the regulations set by The National 
Committee on Health Research Ethics. Chart-
review was conducted for the period of June 2015 
to February 2017.
The study was conducted at two wards, with total 
of 34 beds with speciality in psychosis at the psy-
chiatry hospital, Northern Jutland, Denmark. The 
wards provide mental health services for adults in 
the entire Northern region of Denmark. The psy-
chiatric wards had daily ward rounds and after-
wards a nurse and physicians held team meetings, 
where they assessed all hospitalised patients within 
the wards. The psychiatric wards had never had 
affiliated pharmacists prior to this study. In addi-
tion, the CPs had practical experience (approxi-
mately 5 years) with medication reviews in somatic 
patients, but no experience with psychiatric 
patients. The board of directors at the psychiatric 
hospital requested the CPs not to intervene on 
antipsychotic polypharmacy before counselling. 
This was due mainly to the fact that attending CPs 
at the psychiatric wards was a new initiative, and 
the board of directors wished to avoid resistance 
from physicians. The ultimate goal was to explore 
the potential for identification of DRPs and hence 
improve medicine management in psychiatric 
patients if required.
Two CPs attended the wards weekly and screened 
newly admitted patients. Based on the screening, 
the patients were prioritised with no exclusion for 
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medication review, and patients with the highest 
number of drugs were reviewed first. The next 
week, the CPs followed up on the recommended 
interventions.
The CPs conducted a medication review on patients 
admitted to the wards using patient data from the 
electronic patient chart (EPC) including medical 
record, laboratory data and drug history. The CPs 
identified DRPs with respect to interactions, impair-
ment of body function, duration of treatments, con-
traindications, adverse drug reactions, medication 
reconciliation and untreated indications.
In the process of determination of DRPs, drug 
knowledge, available clinical guidelines and consulta-
tion with nurses and physicians in assessment of the 
patients were utilized, which resulted in a consensus 
to apply. For each identified DRP, a recommended 
intervention was given, and it was also documented 
in the EPC. The DRPs were then discussed with the 
attending physicians who made the final decision 
(accept/reject). If the DRP was accepted, the physi-
cian or the CPs corrected the medication and the 
DPR was implemented. If the attending physician 
was not on the ward, the DRPs were only docu-
mented in EPC. Subsequently, the CPs assessed the 
acceptance or rejection of the recommended inter-
ventions and documented those in the DRP-
database. The CPs also classified each DRP and 
registered those in the DRP-database electronically.
Data handling and analysis
For each DRP, demographic data of the patients 
(age, gender), number of drugs, and date for medi-
cation review were registered in the DRP-database. 
Each DRP was categorized in the DRP-database 
by registration of drug [Anatomical Therapeutic 
Chemical (ATC) code],21 a text field for registra-
tion of the recommendation presented for the phy-
sician and follow-up on the DRPs (accepted and 
implemented, rejected, no/other action identified, 
no action identified, patient discharged).
The DRP-database contains the following 13 cat-
egories: dose, dosing time and interval, side 
effects, interaction, drug form and strength, non-
adherence to guidelines, therapeutic duplication, 
drug allergies, length of treatment, supplement to 
treatment [e.g. PPI (proton-pump inhibitors) to 
NSAID (non-steroidal anti-inflammatory drugs)], 
EPC-related (related to the set-up and use of the 
EPC), inappropriate drug (e.g. NSAID when 
having ulcer) and no DRP identified.22
Each DRP was registered with one ATC-code 
and, when relevant, with, for example, two inter-
actions. Consequently, the number of drugs is 
higher than the numbers of DRPs.
The DRP-database also contained one unauthor-
ised ATC-code; Z02 (= no specific drug was 
involved). Z02 was used to register missing clinical 
data such as lack of monitoring of electrocardio-
gram (ECG), blood pressure and laboratory data.
The data were extracted from the DRP-database 
to Microsoft Excel® v. 2013 and were used for 
further analysis. The data were analysed using 
descriptive statistics and presented as frequencies 
and percentages. Furthermore, we tested if any 
correlation existed between number of prescribed 
drugs and average number of DRPs, by applica-
tion of Pearson correlation test to identify the cor-
relation coefficient and p value; a p value below 
0.05 was considered significant. For this test, 
SigmaPlot 14.0 was used.
Results
In total, 1385 DRPs were identified; 788 (57%) 
DRPs were discovered in females (mean age 48; 
range 18– 81 year) and 597 (43%) DRPs were dis-
covered in males (mean age 45; range 20–79 years).
The CPs performed 607 medication reviews dur-
ing the study period (June 2015 to February 
2017). A total of 81 (13%) patients with no DRP 
identified were excluded from further analysis. 
The remaining patients [526 (87%)] had 1304 
DRPs, which were presented for the physicians. 
The average number of DRPs per medication 
review was 2.5 (σ = 2.84).
With an increasing number of drugs prescribed, 
the average number of DRP increased. Figure 1 
shows the correlation with a correlation coeffi-
cient of 0.811.
In the study population, 418 (79%) patients had 
more than 5 drugs, 192 (37%) patients had more 
than 10 drugs, and 62 (12%) patients had more 
than 15 drugs. Of the 1304 DRPs, 404 (31%) 
DRPs were registered with two ATC-codes, 
which resulted in 1708 drugs. Table 1 shows an 
overview of the DRPs categories included in the 
most intervened drug in each category. The fre-
quency of DRP categories varied, with the most 
frequent being ‘drug dosage’ (n = 259, 19.9%), 
followed by ‘inappropriate drug’ (n = 212, 
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16.3%), ‘interactions’ (n = 203, 15.6%), and ‘side 
effect’ (n = 154, 11.8%), which together com-
prised more than 60% of the DRPs.
It is worth mentioning that many drug–drug inter-
actions are resulted from cytochrome P450 enzy-
matic reactions that can be induced or inhibited 
by drugs, leading to clinically significant conse-
quences for example, unanticipated adverse reac-
tions or therapeutic failures. CYP 2D6, 2C19 and 
2C9 are the most commonly studied cytochrome 
P450 enzymes, and several pharmacogenetic fac-
tors have been identified where CYP enzymes are 
involved in treatment-associated side effects of 
psychotropic drugs.23
The most frequently represented drugs in the top 
three of the categories were olanzapine, quetia-
pine and pantoprazole. Olanzapine was the top in 
the following five DRP types; interactions, side 
effects, dosing time and interval, drug form and 
strength, and drug allergies (Table 1).
Figure 2 summarises the overall distribution of 
drugs according to ATC-class. ATC N (nervous 
system), ATC A (alimentary tract and metabo-
lism) and ATC C (cardiovascular system) were 
the most frequent ATC-classes, and contributed 
to 80.7% (n = 1379) of all the DRPs.
Olanzapine, quetiapine and paracetamol were 
the drugs present most frequently in ATC N 
(nervous system), and pantoprazole, vitamin 
B-complex and cholecalciferol were the drugs 
most frequent in ATC A (alimentary tract and 
metabolism). Within ATC C (cardiovascular 
system), simvastatin, atorvastatin and omega-
3-triglycerides were the most frequent drugs 
(Table 2).
The three drug groups (psycholeptics, psychoan-
aleptics and drugs for acid related disorders) 
comprised 41.9% of all DRPs. Examples of these 
drugs are illustrated in Table 3, with categories 
and suggested intervention.
The overall acceptance rate of the DRPs was 641 
(49%) and the implementation rate was 429 
(33%). In 212 (16.3%) of the accepted DRPs, the 
recommended intervention was not followed, or 
another action was taken (Figure 3).
The group ‘not-accepted’ accounts for 23.5% of 
DRPs, where ‘no action identified’ comprises 
22% of the DRPs. For the 288 (94%) ‘not-
accepted’ DPRs it was not possible to detect any 
acceptance or implementation during follow up, 
and therefore it was categorized as ‘no action 
identified’. The psychiatric physician rejected 
only 18 (5.9%).
DRPs were categorised with no information 
about acceptance and implementation (n = 357, 
27.4%) when patients were discharged before fol-
low up was possible.
Discussion
In this pharmaco-utilisation study, we found an 
average of 2.5 DRPs per medication review and 
Figure 1. Correlation between number of drugs prescribed and the average number of DRP (Pearson 
correlation with coefficient of 0.811 and p value of 0.000000512).
DRP, drug-related problem.
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the more drugs prescribed, the more DRPs were 
registered. The most frequent DRP-categories 
were drug dosage, inappropriate drugs and inter-
actions, despite the fact that many drugs were 
involved; the most frequent drugs were olanzap-
ine, quetiapine and pantoprazole. For the drugs 
where a follow up was possible, an overall accept-
ance rate was 49% and the implementation rate 
was identified as 33%.
Rate of DRP occurrence and correlation with 
multiple factors in the psychiatric wards’ 
pharmacotherapy
In a systematic review, the average DRP rate var-
ied from 0.13 to 10.6 per patient in different medi-
cal departments and the average DRP of 2.5 in the 
present study falls within the current reported 
range.24 However, the majority of the studies 
included in the review found an average DRP rate 
Table 1. Frequency of DRP categories.
DRP category n (%) Top three most frequent intervened drugs (n)
Drug dosage 259 (19.9) Pantoprazcole (61)
Vitamin B-complex (18)
Paracetamol (16)
Inappropriate drug 212 (16.3) Zopiclone (20)
Paracetamol (16)
Ibuprofen (11)
Interactions 203 (15.6) Olanzapine (38)
Clozapine (19)
Quetiapine (18)
Side effects 154 (11.8) Quetiapine (40)
Risperidone (19)
Olanzapine (16)
Supplement to treatment 83 (6.4) Vitamin B-complex (14)
Colecalciferol (11)
Simvastatin (9)
Length of treatment 79 (6.1) Z02 (8)
Oxazepam (5)
Clonazepam; ibuprofen; paracetamol; zopiclone (4)
Dosing time and interval 77 (5.9) Olanzapine (9)
Simvastatin (8)
Disulfiram; pantoprazole (5)
Medication reconciliation 65 (5.0) Colecalciferol; potassium chloride (5)
Furosemide (4)
Drug form and strength 62 (4.8) Aripiprazole; olanzapine; quetiapine; risperidone; tramadol (5)
Non-adherence to guidelines 43 (3.3) Pregabalin (13)
Metoprolol; Tramadol (3)
Therapeutic duplication 28 (2.1) Salbutamol (5)
Quetiapine (4)
Melatonin; mirtazapine (3)
EPC-related 23 (1.8) Z02 (5)
Risperidone (4)
Other drugs (1)
Drug allergies 16 (1.2) Z02 (12)
Chlorprothixene; beta-lactam antibacterial, penicillin; nicotine; olanzapine (1)
DRP, drug-related problem; EPC, electronic patient chart.
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Figure 2. Frequency of drug groups at ATC 1st level.
ATC, anatomical therapeutic chemical; DRP, drug-related problem.
Table 2. Frequency of drug group at ATC level 2 with most common drug within the drug group.
ATC level 2 Drug groups n (%) Most common drug within drug group n (%)
N05  Psycholeptics 465 (27.2) Olanzapine 85 (5.0)
 Quetiapine 84 (4.9)
 Risperidone 42 (2.5)
N06  Psychoanaleptics 135 (7.9) Escitalopram 28 (1.6)
 Citalopram 25 (1.5)
 Sertraline 25 (1.5)
A02  Drugs for acid related disorders 116 (6.8) Pantoprazole 84 (4.9)
 Magnesium oxide 11 (0.6)
 Omeprazole 11 (0.6)
N02  Analgesics 113 (6.6) Paracetamol 44 (2.6)
 Tramadol 41 (2.4)
 Morphine 18 (1.1)
A11  Vitamins 110 (6.4) Vitamin B-complex 40 (2.3)
 Colecalciferol 31 (1.8)
 Thiamine (vitamin B1) 27 (1.6)
N03  Antiepileptic 93 (5.4) Lamotrigine 20 (1.2)
 Valproic acid 17 (1.0)
ATC, anatomical therapeutic chemical.
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lower than in the present study. The differences in 
average DRP can be explained by the difference in 
the methods of conducting medication reviews and 
the number of medications prescribed per patient. 
This study included very ill inpatients at psychiat-
ric wards with a high average number of drugs, and 
this may consequently cause a higher average DRP 
number.15,18,25–27 It is also important to mention 
that different DRP categorisation methods have 
been used and many departments were involved24; 
hence, a direct comparison is not possible. 
Furthermore, the skills and clinical experience of 
the CPs and the physicians involved may influence 
the results.19,24,28 In addition, the average DRP in 
this study could be higher because the CPs did not 
comment on antipsychotic polypharmacy.
The present study found that the numbers of pre-
scribed drugs correlated with the increased num-
ber of DRPs. This result is in accordance with 
previous studies,15,18,25–27 and it is important to 
take this into account particularly among psychi-
atric patients because their pharmacotherapy is 
often highly complex due to both somatic and 
psychiatric illnesses.
The CPs were able to propose a large number of 
DRPs related to all available categories investi-
gated in the present study; however, the four most 
frequent DRPs consisted of ‘drug dosage’ (19.9%) 
followed by ‘inappropriate drug’ (16.3%), ‘inter-
actions’ (15.6%) and ‘side effects’ (11.8%). The 
most frequent category of recommendation was 
Table 3. Examples of interventions on the three most frequent drugs reported in the DRP-database.
Drug Intervention Category
Quetiapine Be aware of anticholinergic side effects. The patient is prescribed quetiapine, orphenadrine 
and prometazine, which increase the anticholinergic burden.
Side effect
Quetiapine ECG monitoring is recommended, since methadone and quetiapine can cause  
QT-prolongation.
Side effect
Olanzapine Be aware of the effect of olanzapine. Citalopram can cause increased effect of olanzapine, due 
to inhibiting CYP2D6 that metabolises olanzapine.
Interaction
Olanzapine Be aware of increased effect of olanzapine due to increased concentration of olanzapine in the 
blood, when using nicotine substitution.
Interaction
Pantoprazole Please consider whether the dosage of pantoprazole 40 mg can be reduced to 20 mg or the 
prescription can be discontinued.
Drug dosage
DRP, drug-related problem; ECG, electrocardiogram.
Figure 3. Acceptance and implementation of DRPs.
DRP, drug-related problem.
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‘drug dosage’ and similar findings were identified 
in other international studies.5,18,22,29–31 Several 
studies have shown other categories as the most 
frequent DRP, for example, inappropriate drugs, 
interactions, drug choice problem and non- adherence 
to guidelines.26,27,32,33 It is not clear as to what reason 
the adherence is poor and, to identify the potential 
reasons and seek solutions, further studies are 
required. However, it might be speculated that this 
factor might be a consequence of the  complexity 
that exists within pharmacotherapy of  psychiatric 
disorders. In addition, habits and clinical practice 
experience might influence prescription more 
than careful counselling with updated guidelines.
The differences between reported frequencies can 
be explained by the variation in ward settings, dif-
ferent focus on DRPs by the CPs, different clas-
sification system and methods. Despite different 
results, the dosage is often described in the litera-
ture as a DRP, which indicates that dosage has 
the potential to cause DRPs and requires atten-
tion by the prescribing physician.
A recent study performed by Soerensen et al. at 
the psychiatric department of Aalborg University 
hospital investigated potentially inappropriate 
prescribing (PIP) of psychotropic and somatic 
medications in inpatient units.15 The most fre-
quent PIPs in this study were found to be ‘inter-
actions between drugs’ (36%) and ‘too high doses 
of drugs’ (16%).15 In another psychiatric setting 
in Billings (MT, USA), the most common identi-
fied DRPs were ‘adverse drug reaction’ (27%), 
‘unnecessary medication’ (20%), and ‘dose too 
high’ (13%).34 These findings concur with the 
current study results.
DRPs occurrence and ATC-classes
The most common ATC-classes (ATC level 1) 
intervened upon in this study were ‘nervous sys-
tem’ (n = 894), ‘alimentary tract and metabolism’ 
(n = 343) and ‘cardiovascular system’ (n = 142). 
This is consistent with other studies.27,31 Even 
though these three ATC-classes contributed in 
total to 80.7% of all DRPs, the DRPs consisted of 
several drug classes, due to the complexity of the 
pharmacotherapy in psychiatric patients.
A large proportion of the DRPs in this study 
involved somatic medicines (e.g. simvastatin, 
ibuprofen, pantoprazole). The physician at the 
involved wards indicated that they have limited 
knowledge of somatic medicines. Therefore, the 
CPs recommended interventions that were 
extremely relevant due to the high mortality 
among psychiatric patients due to physical 
illness.35,36
In this study, ‘psycholeptics’ (N05, ATC level 2) 
were the most common intervened drug group 
(n = 465, 27.2%); however, the severity of the 
DRPs was not assessed. Nevertheless, Soerensen 
et al. found PIPs were potentially serious for inpa-
tients at psychiatric wards and especially the use 
of antipsychotics and antidepressants were associ-
ated with PIPs.15 The most frequent intervened 
drugs in this study were olanzapine and quetia-
pine, both antipsychotics, and these drugs may 
pose a higher risk for causing DRPs.
Some drugs are considered as high-risk drugs, 
and analgesics are in this category.37 NSAIDs 
(ibuprofen), opioids (tramadol, morphine) and 
paracetamol were represented in the present 
study as frequent drugs, which indicated that 
analgesics prescribed for psychiatric patients 
should be a field of attention.
DRPs occurrence, acceptance and 
implementation
In the present study, 49% of the recommended 
interventions were accepted and the physicians 
implemented 33%. A total of 27% percentage of 
the patients were discharged before follow up, and, 
in 22% of the recommended interventions, no 
action was identified. The acceptance and imple-
mentation rates may be even higher than suggested 
by our findings, because some of the recommended 
interventions were implemented but not registered 
in the DRP-database by the CPs before the patients 
were discharged. In addition, some recommended 
interventions were not implemented until later in 
the admission or after discharge by the general 
practitioner, and in some cases the physician 
accepted the recommended intervention, but it 
was not implemented, because the patient did not 
want to change the medication.
A systematic review has identified that acceptance 
rates for pharmacist interventions in hospitalised 
patients vary between 39% and 100%.24 However, 
one should consider that the definition of accept-
ance and the study design could be different 
among different studies; if, for example, the dis-
charged patients were excluded in the present 
study, the acceptance rate would have been 68% 
and the implementation rate 45%.
KP Kibsdal, S Andersen et al.
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It has been suggested that the physician accept-
ance rate depends on the relationship between the 
prescribing physician and the CP.19,31 In one of 
the wards in the present study, there was a high 
turnover of physicians, which could influence the 
implementation rate because it was time consum-
ing to obtain a good relationship between the CPs 
and the physician. Another explanation of varia-
tion in the implementation rate is the communi-
cation of the recommended interventions. Studies 
have shown that when communication was oral, 
the implementation rate was higher, compared 
with electronic communication of interven-
tions.9,31,33 In the present study, the communica-
tion of some of the recommended interventions 
was only in the EPC because there were no physi-
cians on the wards.
Study limitations
This study was the first of its kind to highlight the 
value and importance of systematic medication 
reviews for all patients by CPs as an important 
step towards improving patient safety in psychiat-
ric hospitals. Our findings paved the way for 
awareness towards DRPs, specifically drug dosage 
problems, inappropriate drug prescriptions and 
interactions within psychiatric wards in Denmark. 
However, like all first-time studies we faced some 
limitations. We included only psychiatric inpa-
tients in the Northern region of Denmark; hence, 
this may affect generalisability to other regions. 
Entering errors might have occurred while enter-
ing data in the DRP-database, this is due to the 
fact that data entry was not controlled by another 
person in our study. However, the DRP-database 
has been validated, and demonstrated to have 
high reliability and reproducibility.20
Our CPs had no experience with medication 
reviews in psychiatric patients at the beginning of 
the study and additionally, the CPs were a new 
profession in the psychiatric departments, which 
required an adoption period for both the CPs and 
the physicians. Some studies used experienced 
pharmacists.19,24 Furthermore, the introduction of 
the CPs was not discussed with the team at the 
wards prior to the project, which may have had 
implications for the acceptance of the DRPs. In 
addition, we did not assess the clinical relevance 
and severity of the DRPs. It was the CPs who 
decided if the finding was a DRP and no 
 independent arbiter was included in the decision-
making process. For the future studies, it would 
be valuable to consider a study design where 
review of the retrospective information can be fol-
lowed by a cohort of patients exposed to same 
treatment modalities (best matched with overlap-
ping diagnoses and severity) to identify whether, 
and how, vulnerability factors might play a role 
besides pharmacological rationales in experienc-
ing a DRP. In addition, stratification of outcome 
would be optimal if presented across different 
diagnoses, the severity of the index episode at 
treatment (in case of phasic or multi-polarity ill-
ness), history for therapeutic resistance, and 
comorbidity-associated issues. In addition, to 
enhance the clinical value of subsequent studies, 
recommendations offered as actions on identified 
DRPs must be formulated clearly to both raise 
concern and awareness, and to provide actions 
that can be used clinically. In this study, we have 
mostly raised awareness in combination with 
alternative ways put forward. However, recom-
mendations can be improved with a consensus 
among the clinical team on a ward and CPs to 
identify optimal interventions for implementation.
One must also consider that, since a welfare health 
care system is established in Denmark, insurance 
issues are not problematic compared with other 
countries in which a welfare-based healthcare sys-
tem might not be implemented. This aspect of 
DRPs must also be taken into account when con-
ducting future studies of this kind.
Conclusion
Among psychiatric patients, DRPs were com-
monly observed, particularly in patients with mul-
tiple prescribed drugs. Our findings demonstrated 
that drug dosage, inappropriate drugs, and drug 
interactions were critical elements in the forma-
tion of DRPs. Olanzapine, quetiapine and panto-
prazole were the drugs observed most frequently 
among the identified DRPs, which suggest higher 
attention should be paid to classes of psycholep-
tics, psychoanaleptics and drugs for acid-related 
disorders amongst psychiatric patients. This study 
provided first evidence that medication reviews con-
ducted by CPs could help in identification of DRPs 
and application of corrections; hence,  strategies to 
integrate CPs in psychiatric wards to minimise 
DRPs are recommended.
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